Cargando…
Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput
The current drug development pipeline takes approximately fifteen years and $2.6 billion to get a new drug to market. Typically, drugs are tested on two-dimensional (2D) cell cultures and animal models to estimate their efficacy before reaching human trials. However, these models are often not repre...
Autores principales: | Maloney, Erin, Clark, Casey, Sivakumar, Hemamylammal, Yoo, KyungMin, Aleman, Julio, Rajan, Shiny A. P., Forsythe, Steven, Mazzocchi, Andrea, Laxton, Adrian W., Tatter, Stephen B., Strowd, Roy E., Votanopoulos, Konstantinos I., Skardal, Aleksander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074680/ https://www.ncbi.nlm.nih.gov/pubmed/32085455 http://dx.doi.org/10.3390/mi11020208 |
Ejemplares similares
-
In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening
por: Mazzocchi, Andrea R., et al.
Publicado: (2018) -
Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research
por: Forsythe, Steven D., et al.
Publicado: (2022) -
Exploration of Dynamic Elastic Modulus Changes on Glioblastoma Cell Populations with Aberrant EGFR Expression as a Potential Therapeutic Intervention Using a Tunable Hyaluronic Acid Hydrogel Platform
por: Sivakumar, Hemamylammal, et al.
Publicado: (2017) -
Multi-Cell Type Glioblastoma Tumor Spheroids for Evaluating Sub-Population-Specific Drug Response
por: Sivakumar, Hemamylammal, et al.
Publicado: (2020) -
Detection of lineage-reprogramming efficiency of tumor cells in a 3D-printed liver-on-a-chip model
por: Lu, Zuyan, et al.
Publicado: (2023)